H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating.
Protagonist Therapeutics Inc (PTGX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 6,144,006 | $536,617,484 | -1% | 2.53% |
| 2. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,408,772 | $123,042,146 | -3% | 0.48% |
| 3. | Perceptive Advisors Joseph Edelman | 1,350,425 | $117,946,120 | +32% | 2.1% |
| 4. | Citadel Investment Group Ken Griffin | 1,126,687 | $98,404,842 | +374% | 0.01% |
| 5. | Driehaus Capital Richard Driehaus | 1,099,170 | $96,001,508 | -4% | 0.65% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.70 | 12,000 | $80,400.00 | 15,310 | 2020-03-12 | Filing | |
| $5.70 | 8,000 | $45,620.00 | 8,000 | 2019-12-03 | Filing | |
| $5.13 | 30,000 | $153,900.00 | 49,500 | 2019-12-03 | Filing | |
| $5.09 | 562 | $2,860.58 | 1,175 | 2019-12-03 | Filing | |
| $5.10 | 613 | $3,126.30 | 613 | 2019-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.42 | 18,000 | $1,483,560.00 | 7,825 | 2026-02-17 | Filing | |
| $83.68 | 20,000 | $1,673,600.00 | 7,825 | 2026-02-06 | Filing | |
| $83.19 | 4,068 | $338,416.92 | 574,505 | 2026-01-27 | Filing | |
| $84.05 | 14,205 | $1,193,930.25 | 574,505 | 2026-01-26 | Filing | |
| $84.00 | 10,685 | $897,540.00 | 574,505 | 2026-01-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,715,999 | $848,595,367 | 0.01% | |
| 2. | 5,413,690 | $472,831,684 | 0.01% | |
| 3. | 5,059,053 | $441,857,689 | 4.43% | |
| 4. | 3,199,729 | $279,464,331 | 0.01% | |
| 5. | 3,171,423 | $276,992,086 | 0.05% |
News See All
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
We came across a bullish thesis on Protagonist Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on PTGX.
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX.
Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now.
11 Best Mid Cap Growth Stocks To Invest In Now
On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC's 'Closing Bell Overtime' to talk about how the market sell-off is an opportunity to step in.
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a ‘Buy’ rating and a $72 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Hedge Fund Resource Center Billionaire Hedge Funds
